"Structured research brief for hypothesis h-var-b7e4505525"
Comparing top 3 hypotheses across 8 scoring dimensions
Multi-agent debate between AI personas, each bringing a distinct perspective to evaluate the research question.
Generates novel, bold hypotheses by connecting ideas across disciplines
Title: EC-II SST interneuron inhibition of PV+ basket cells paradoxically enhances gamma power through synchronized peri-somati
...Title: EC-II SST interneuron inhibition of PV+ basket cells paradoxically enhances gamma power through synchronized peri-somatic disinhibition
Mechanism:
SST interneurons in EC-II primarily target the distal dendrites of PV+ basket cells, releasing them from tonic inhibition and allowing phase-amplitude coupling that synchronizes pyramidal cell ensembles at gamma frequencies.
Target: SST-GABAₐα5 subunit signaling; PV+ cell network
Supporting Evidence:
Confidence: 0.72
Title: Transcranial focused ultrasound activates Piezo1/TRPML1 channels on EC-II SST interneurons to restore perforant path synaptic strength
Mechanism:
tFUS generates microbubbles and shear forces that activate mechanosensitive ion channels (Piezo1, TRPML1) on SST interneurons, triggering Ca²⁺-dependent signaling cascades that enhance BDNF release and restore glutamatergic transmission at EC→dentate gyrus synapses impaired in AD.
Target: Piezo1 (PMID: 33432326), TRPML1 (PMID: 28716887), BDNF/TrkB pathway
Supporting Evidence:
Confidence: 0.68
Title: Gamma restoration normalizes expression of AD risk genes (APOE4, TREM2) in EC-II microcircuits through feedforward excitation normalization
Mechanism:
Amyloid-β oligomers induce theta-gamma coupling collapse in EC→hippocampus circuits. Restoring gamma through SST-mediated inhibition suppresses aberrant hyperactivity, downregulating APOE4 expression in astrocytes and TREM2 in microglia, reducing neuroinflammation.
Target: APOE/ABCA1 signaling, TREM2-SYK pathway, Aβ clearance
Supporting Evidence:
Confidence: 0.61
Title: Closed-loop tFUS synchronized to hippocampal theta optimizes EC-II SST recruitment for ripple-gamma coupling restoration
Mechanism:
Hippocampal ripples (150-200 Hz) nested within gamma are critical for memory consolidation. SST interneurons gate the timing of sharp-wave ripples; closed-loop tFUS delivered at theta trough maximizes SST activation during ripple generation windows.
Target: Theta-ripple coupling machinery; SST-NMDA receptor subunit composition (GluN2B)
Supporting Evidence:
Confidence: 0.74
Title: SST interneuron-mediated gamma restoration normalizes HCN1 hyperpolarization-activated currents in EC-II stellate cells
Mechanism:
HCN1 channels control temporal integration in grid cells; in AD, Aβ oligomers enhance HCN1-mediated Ih currents, degrading grid firing and spatial coding. Gamma-range SST inhibition normalizes membrane time constants, restoring grid cell function and downstream hippocampal indexing.
Target: HCN1 (HCN1), hyperpolarization-activated cyclic nucleotide-gated channels
Supporting Evidence:
Confidence: 0.58
Title: tFUS-activated EC-II SST interneurons restore astrocyte glycolytic coupling, enhancing ATP-sensitive K⁺ channel function in pyramidal neurons
Mechanism:
AD brains exhibit impaired astrocyte-neuron lactate shuttle (ANLS). SST interneuron activation triggers astrocytic Ca²⁺ waves via ATP release, stimulating glycolysis and lactate provision to EC-III pyramidal neurons, restoring their capacity for gamma generation.
Target: Astrocytic MCT1/4 (lactate transporters), neuronal pannexin-1 ATP release, KATP channels
Supporting Evidence:
Confidence: 0.55
Title: Restored gamma oscillations decrease pro-inflammatory microglial activation in EC via CRHR1-mediated SST-neuroimmune signaling
Mechanism:
SST interneurons express CRHR1 receptors; their activation releases SST, which binds to microglia SSTR2, suppressing NF-κB signaling and IL-1β/IL-6 release. This breaks the cycle between neural circuit dysfunction and neuroinflammation in AD.
Target: CRHR1-SST-SSTR2 axis; NF-κB/TNF-α pathway; P2X7R
Supporting Evidence:
Confidence: 0.62
| # | Hypothesis | Primary Target | Confidence |
|---|------------|----------------|------------|
| 1 | SST→PV disinhibition | GABAₐα5/PV | 0.72 |
| 2 | tFUS mechanosensitivity | Piezo1/BDNF | 0.68 |
| 3 | Gamma-AD gene normalization | APOE4/TREM2 | 0.61 |
| 4 | Closed-loop theta-gamma coupling | CRHR1/NMDA | 0.74 |
| 5 | HCN1 grid cell restoration | HCN1 channels | 0.58 |
| 6 | Astrocyte lactate shuttle | MCT1/4, KATP | 0.55 |
| 7 | SST-microglial anti-inflammation | CRHR1/SSTR2 | 0.62 |
Primary Research Gaps: Direct electrophysiological validation of EC-II SST→PV disynaptic gamma mechanism in AD models; mechanistic specificity of tFUS mechanotransduction in vivo; closed-loop timing optimization in aged animals.
Challenges assumptions, identifies weaknesses, and provides counter-evidence
This research brief proposes an integrated neuromodulation strategy targeting EC-II SST interneurons to restore hippocampal gamma oscillations in Alzheimer's disease. While the hypotheses are mechanistically creative, several suffer from internal inconsistencies, overreach the evidence, or lack falsifiabi
...This research brief proposes an integrated neuromodulation strategy targeting EC-II SST interneurons to restore hippocampal gamma oscillations in Alzheimer's disease. While the hypotheses are mechanistically creative, several suffer from internal inconsistencies, overreach the evidence, or lack falsifiability. Below I evaluate each hypothesis systematically.
1. Mechanistic Contradiction
The core claim—that SST interneuron inhibition of PV+ basket cells paradoxically enhances gamma—is physiologically counterintuitive. PV+ basket cells are canonical gamma pacemakers (Cardin et al., 2009); their inhibition should reduce rather than augment gamma power. The "disinhibition" framing requires clarification: disinhibition of what, and through what synaptic cascade?
2. Connectivity Specificity
The cited evidence (Sohal et al., 2009) describes SST→PV connectivity in CA1, not EC layer II specifically. EC-II contains different interneuron subtypes (grid cells, stellate cells, and local interneurons) with potentially distinct SST→PV coupling ratios. The assumption that EC-II SST mirrors hippocampal SST function is unsubstantiated.
3. Temporal Precision Problem
Gamma oscillations require PV-mediated fast-spiking with <5 ms precision. If SST cells provide delayed inhibition (as argued), how does this synchronize rather than desynchronize pyramidal ensembles?
| Falsification Strategy | Predicted Outcome | Interpretation |
|------------------------|------------------|----------------|
| Optogenetic activation (not silencing) of EC-II SST during tFUS | If SST inhibits PV, activation should reduce gamma; if hypothesis correct, gamma should increase | Disconfirms if activation reduces gamma |
| Paired recordings from identified EC-II SST→PV connections | Direct physiological evidence of synaptic weight | Disconfirms if connectivity is absent |
| pharmacological GABAₐα5 blockade | If α5-containing receptors mediate SST→PV effect, antagonist should prevent gamma restoration | Weakens if non-α5 mechanisms dominate |
Rationale: The core mechanism is contradictory without a clear disinhibition cascade; EC-II specificity is assumed rather than demonstrated. Requires unambiguous circuit-level evidence in EC-II slice preparations before proceeding to tFUS validation.
1. Mechanistic Extrapolation
The claim that tFUS activates Piezo1/TRPML1 in vivo to trigger Ca²⁺-dependent BDNF release is highly speculative. Most tFUS neuromodulation evidence points to:
2. Target Specificity Paradox
tFUS is inherently low-spatial-resolution (~mm scale). The proposal to target "Piezo1/TRPML1 on SST interneurons" is anatomically implausible with current tFUS technology. Non-targeted cells would also experience mechanical forces, questioning specificity.
3. BDNF Source Ambiguity
Even if mechanosensitive channels activate, BDNF release from SST interneurons specifically is not established. BDNF typically originates from excitatory neurons; SST interneuron BDNF contribution to EC→DG synaptic maintenance is unclear.
| Falsification Strategy | Predicted Outcome | Interpretation |
|------------------------|------------------|----------------|
| Conditional Piezo1 knockout in SST-Cre mice | If Piezo1 is necessary, tFUS effects on EPSC restoration should disappear | Weakens mechanism if effects persist |
| Compare tFUS vs. direct TrkB agonist (7,8-DHF) on EPSC restoration | Equivalent effects suggest BDNF pathway downstream but not mechanosensitive-specific | Weakens if direct TrkB activation is more effective |
| Measure SST-specific BDNF release with genetically encoded BDNF sensors | Direct evidence of mechanosensitive BDNF release from identified SST cells | Disconfirms if BDNF release is from other cell types |
Rationale: While mechanosensitivity is biologically plausible, the specific channel involvement, in vivo applicability, and BDNF-source specificity are all unverified. The target specificity problem is severe.
1. Overreach in Causal Chain
The proposed mechanism involves: gamma restoration → suppression of aberrant activity → downregulation of APOE4/TREM2 expression → reduced neuroinflammation. Each step requires separate validation and involves multiple confounding variables (cell-autonomous effects, systemic inflammation, astrocyte dysfunction).
2. Cell-Type Specificity Assumptions
The claim that restored gamma specifically normalizes APOE4 in astrocytes and TREM2 in microglia assumes gamma oscillations preferentially affect gene transcription in these non-neuronal populations. There is no established mechanism linking neural oscillations to transcriptional regulation in glia.
3. APOE4 Paradox
APOE4 is expressed throughout life and its effects are developmental as well as adult. Gamma restoration in symptomatic AD may be insufficient to reverse years of APOE4-driven pathology; the transcriptional normalization model is likely oversimplified.
| Falsification Strategy | Predicted Outcome | Interpretation |
|------------------------|------------------|----------------|
| Perform scRNA-seq pre/post tFUS in APP/PS1 mice | Expect transcriptional normalization if hypothesis correct | Weakens if gene expression changes are absent or opposite |
| Isolate astrocyte and microglia transcriptomes separately | Cell-type resolution of gene expression changes | Weakens if neuronal changes occur without glial normalization |
| Use CRISPRi to artificially maintain high APOE4/TREM2 expression | If gene normalization is necessary for tFUS benefit, benefit should be abolished | Tests causality directly |
Rationale: The transcriptional coupling hypothesis is highly speculative and requires extensive intermediate validation. Gene expression is influenced by countless factors; attributing normalization specifically to gamma restoration is premature.
1. Technical Feasibility Concerns
Closed-loop tFUS at <5 ms temporal resolution and <1 mm spatial resolution is not currently achievable with commercial tFUS systems. Ultrasound neuromodulation operates on timescales of seconds, not milliseconds. The proposed "theta trough" targeting assumes real-time theta phase detection and sub-cycle tFUS delivery.
2. Theta-Phase Specificity Overstated
The claim that theta trough stimulation maximizes SST recruitment lacks direct EC-II electrophysiology evidence. Most closed-loop tFUS studies use phase-binned stimulation without the temporal precision required (Nightingale et al., 2022 used 40 Hz entrainment, not phase-specific targeting).
3. NMDA Receptor Evidence Weak
SST-NMDA subunit composition (GluN2B) is mentioned but not tied mechanistically to the closed-loop benefit. The theta-gamma coupling argument is plausible but the specific NMDA target is unexplained.
| Falsification Strategy | Predicted Outcome | Interpretation |
|------------------------|------------------|----------------|
| Compare theta-phase-locked vs. random-phase vs. open-loop tFUS | If closed-loop is superior, phase-locked should outperform alternatives | Weakens if open-loop is equivalent |
| Test closed-loop tFUS in aged (>18 month) 3xTg mice | Aged animals may have blunted theta-gamma coupling responses | Weakens if closed-loop offers no advantage over simple open-loop |
| Chronically implant EEG for real-time theta detection (wireless) | Verify that closed-loop delivery occurs at intended theta phase | Weakens if system cannot achieve <5 ms precision |
Rationale: The conceptual framework is sound (theta-gamma coupling is well-established), but the technical claims overreach current capabilities. However, this is the most promising hypothesis because the closed-loop strategy is theoretically sound even if specific parameters need validation.
1. Disconnection Between Gamma and HCN1
The link between gamma oscillations and HCN1 trafficking/normalization is not established. Aβ-enhanced HCN1 trafficking (Bojnar et al., 2021) is a distinct pathology from gamma desynchronization. Restoring gamma does not directly address Aβ-mediated channel trafficking.
2. Grid Cell Evidence Limitations
Grid cell dysfunction in AD is inferred, not directly demonstrated. Most evidence comes from spatial memory deficits, not EC electrophysiology recordings in AD models.
3. Temporal Scale Mismatch
HCN1 channels operate at subthreshold voltages to control integration windows (10-100 ms). Gamma oscillations (25-40 ms cycles) may influence but not directly normalize HCN1 function.
| Falsification Strategy | Predicted Outcome | Interpretation |
|------------------------|------------------|----------------|
| In vivo EC-II tetrode recordings in 5xFAD vs. WT during tFUS | Direct measurement of grid field parameters | Weakens if grid fields are unaffected by gamma restoration |
| Measure HCN1 current density in EC-II stellate cells post-tFUS | Direct biophysical validation of HCN1 normalization | Disconfirms if currents remain enhanced |
| Use HCN1 blocker (ZD7288) during tFUS | If gamma restoration requires HCN1 normalization, blocker should attenuate benefit | Weakens mechanism specificity |
Rationale: The pathway from gamma restoration to HCN1 normalization is not mechanistically coherent. The grid cell focus is interesting but tangential to the core hypothesis.
1. Cell-Type Specificity Problem
SST interneuron activation triggering astrocytic Ca²⁺ waves via ATP requires intermediary signaling not described. The mechanistic chain (SST activation → ATP release → astrocyte Ca²⁺ → glycolysis → lactate → EC-III pyramidal neurons) involves multiple unvalidated steps.
2. ANLS Evidence in AD is Weak
The astrocyte-neuron lactate shuttle hypothesis itself is controversial (Newman et al., 2011; DOI: 10.1016/j.cell.2011.10.012). Direct evidence for astrocyte-to-neuron lactate transfer supporting specific neural functions is limited.
3. tFUS Effects on Astrocyte Metabolism
tFUS may affect astrocyte function independently of neuronal SST targeting. Disentangling direct vs. indirect effects is challenging.
| Falsification Strategy | Predicted Outcome | Interpretation |
|------------------------|------------------|----------------|
| Block MCT1/4 with AR-C155858; test if tFUS benefits abolished | Validates lactate shuttle requirement | Disconfirms if benefits persist |
| Sensor-based lactate imaging in EC during tFUS | Direct measurement of metabolic changes | Weakens if lactate changes are absent or not cell-type specific |
| ATP sensor imaging (P2X7 receptor-based) | Verify ATP release as intermediary | Weakens if ATP signaling is not observed |
Rationale: The metabolic hypothesis is the most speculative and involves the greatest number of unvalidated intermediate steps. Even if ANLS exists, targeting it via SST-mediated tFUS is indirect and difficult to falsify.
1. CRHR1 Expression on EC-II SST
The claim that EC-II SST interneurons express CRHR1 is not substantiated with cell-type-specific evidence. CRHR1 is primarily a cortical/hypothalamic stress receptor; EC expression is not established.
2. SST-SSTR2 Ligand-Receptor Pairing
SST is released from SST interneurons but also from other sources; the SSTR2 receptor on microglia is identified, but the spatial specificity of SST release to microglial SSTR2 is not addressed.
3. Temporal Sequence Assumptions
The model assumes: tFUS → CRHR1 activation → SST release → SSTR2 activation → NF-κB suppression. Each step requires validation and could operate independently.
| Falsification Strategy | Predicted Outcome | Interpretation |
|------------------------|------------------|----------------|
| CRHR1 antagonist (antalarmin) before tFUS | If CRHR1 is necessary, anti-inflammatory benefits should be blocked | Tests upstream mechanism |
| Conditional SSTR2 knockout in microglia (CX3CR1-CreERT) | If SSTR2 is necessary, microglial phenotype
Assesses druggability, clinical feasibility, and commercial viability
As of April 2026, I would not advance the full hypothesis package as a therapeutic program. I would preserve 3 development-relevant ideas, but substantially narrow them:
As of April 2026, I would not advance the full hypothesis package as a therapeutic program. I would preserve 3 development-relevant ideas, but substantially narrow them:
I would deprioritize or kill the HCN1 grid-cell normalization and astrocyte lactate shuttle hypotheses for now.
Surviving Program A: Closed-Loop Gamma / Theta-Gamma Neuromodulation Feasibility: Moderate. This is the strongest clinical-development concept, but the deliverable should be “adaptive circuit entrainment,” not “EC-II SST interneuron targeting.” Human tFUS can target deep structures with millimeter-scale focal volumes, but cell-type targeting is not realistic with present noninvasive ultrasound. Current LIFU/tFUS reviews still emphasize parameter uncertainty and incomplete mechanism mapping, despite promising human neuromodulation data ([Nature Reviews Methods Primers, 2024](https://www.nature.com/articles/s43586-024-00368-6); [J NeuroEngineering Rehab, 2025](https://jneuroengrehab.biomedcentral.com/articles/10.1186/s12984-025-01753-2)).
Druggability / modality: This is not druggable in the conventional sense. It is a regulated device or device-plus-software product. The actionable “target” is electrophysiologic: hippocampal/entorhinal gamma power, theta-gamma coupling, and network hyperexcitability.
Biomarkers/model systems:
Use EEG/MEG gamma entrainment, sleep/ripple proxies where available, task fMRI, hippocampal/entorhinal MRI volume, amyloid/tau PET, plasma/CSF p-tau217, NfL, GFAP, and cognitive endpoints such as ADAS-Cog, CDR-SB, RBANS, or memory composites. In animals, use AppNL-G-F, 5xFAD, Tau models, and aged WT controls with EC/CA1 LFP plus behavior.
Clinical constraints:
A realistic first-in-human study should not promise memory rescue. Start with mild cognitive impairment or mild AD, amyloid-confirmed, 20-40 participants, sham-controlled, repeated sessions, with EEG entrainment as the primary endpoint and cognition as exploratory. True theta-phase closed-loop delivery at millisecond precision is likely too ambitious initially; adaptive session-by-session parameter tuning is more realistic.
Safety:
Main risks are heating, cavitation, off-target stimulation, headache, dizziness, seizure risk in hyperexcitable patients, skull-related dose variability, and unknown effects of repeated deep-brain stimulation. Use conservative acoustic limits, MR thermometry or validated acoustic modeling, seizure screening, and stopping rules.
Timeline/cost:
Preclinical optimization: 18-30 months, roughly $2-5M.
Pilot human feasibility: 18-24 months, $5-12M.
Pivotal efficacy trial: 4-6 years, likely $40-100M+.
Best-case meaningful clinical signal: 5-8 years.
Surviving Program B: tFUS Modulation of Perforant-Path Synaptic Function Feasibility: Low-to-moderate preclinically; low clinically until mechanism is simplified. The Piezo1/TRPML1/SST/BDNF chain is too specific for current evidence. A better hypothesis is: “low-intensity tFUS can acutely modulate EC-DG/EC-CA1 transmission and plasticity in AD-relevant circuits.”
Druggability / modality:
Again, device-based. Piezo1, TRP channels, BDNF/TrkB, and GABAergic signaling can be pharmacologically perturbed in experiments, but none is ready as a therapeutic co-target without strong necessity data.
Biomarkers/model systems:
Required preclinical package: EC-DG field potentials, paired-pulse ratio, LTP/LTD, calcium imaging, cell-type calcium reporters, SST-Cre/PV-Cre controls, Piezo1 conditional KO or knockdown, and comparison to sham ultrasound. Do not rely on GsMTx4 alone because it is not selective enough.
Clinical constraints:
Clinical translation requires showing a reproducible electrophysiologic effect at safe parameters before any AD efficacy claim. In humans, source-localized EEG/MEG or intracranial epilepsy-patient studies could de-risk timing and circuit engagement before AD trials.
Safety:
Avoid microbubble cavitation unless the program is explicitly BBB opening. For pure neuromodulation, microbubbles add regulatory and hemorrhage/edema complexity. FUS-BBB opening has early AD safety feasibility, including small clinical studies, but it is a different product category ([Theranostics 2024 AD pilot](https://pubmed.ncbi.nlm.nih.gov/39113808/); [FUS-BBBO systematic review/meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC12095960/)).
Timeline/cost:
Mechanism proof in rodents: 2-3 years, $3-6M.
Large-animal/human parameter bridge: 1-2 years, $3-8M.
Not trial-ready as disease-modifying AD therapy before roughly 5 years.
Surviving Program C: Inflammation / Amyloid / Tau as Secondary Pharmacodynamics Feasibility: Moderate as biomarker readout; weak as primary causal mechanism. Gamma stimulation has preclinical and early clinical support, but the claim that gamma directly normalizes APOE4 and TREM2 transcription is too broad. Use glial markers as downstream readouts, not the central thesis. Human gamma stimulation remains promising but not settled; a 2024 meta-analysis of 40 Hz tACS reported cognitive and memory signals, while still noting uncertainty ([PubMed](https://pubmed.ncbi.nlm.nih.gov/39573866/)). Long-term audiovisual gamma data remain small and early ([PMC open-label extension](https://pmc.ncbi.nlm.nih.gov/articles/PMC12552893/)).
Druggability / modality:
No direct druggable target emerges from the proposed APOE/TREM2 normalization story. If combined with drugs, the logical partners are approved/late-stage anti-amyloid antibodies, anti-tau programs, or anti-inflammatory agents, but combination development sharply raises cost and regulatory complexity.
Biomarkers/model systems:
Use amyloid PET, tau PET, plasma p-tau217, GFAP, NfL, cytokine panels, TSPO PET if justified, microglial single-cell RNA-seq in animals, and spatial transcriptomics in EC/hippocampus. APOE/TREM2 expression should be exploratory.
Clinical constraints:
Do not power early trials on plaque reduction or cognition unless there is a strong entrainment and target-engagement signal. Best early endpoint is dose-response target engagement plus safety.
Safety:
Inflammation could improve, worsen, or simply reflect tissue stimulation. Monitor edema, microhemorrhage, ARIA-like MRI changes if combined with antibodies, sleep disruption, agitation, and seizure threshold.
Timeline/cost:
Add-on biomarker module to Program A: incremental $1-5M.
Standalone anti-inflammatory gamma/tFUS claim: not justified without 2-3 years of stronger mechanistic work.
No-Go / Hold Hypothesis 5, HCN1 grid-cell restoration: interesting neuroscience, poor therapeutic tractability. HCN1 normalization is not clearly downstream of gamma entrainment, and in vivo human grid-cell biomarkers are not practical enough for clinical development.
Hypothesis 6, astrocyte lactate shuttle: too indirect. The pathway has too many unvalidated links, difficult biomarkers, and no clear intervention lever.
Hypothesis 1, SST→PV disinhibition: keep only as a circuit-mechanism experiment. It is not yet a development-grade therapeutic rationale because EC-II SST targeting and SST→PV gamma enhancement are not established enough.
Bottom line: the investable version is a noninvasive adaptive gamma-entrainment device program for early AD, with tFUS as one candidate modality and EEG/MEG target engagement as the first gate. The SST/Piezo/HCN1/lactate/CRHR1 details should be treated as exploratory biology until they survive direct cell-type and circuit validation.
Following multi-persona debate and rigorous evaluation across 10 dimensions, these hypotheses emerged as the most promising therapeutic approaches.
Interactive pathway showing key molecular relationships discovered in this analysis
graph TD
gamma_entrainment["gamma entrainment"] -.->|inhibits| Amyloid_Plaque_Burden["Amyloid Plaque Burden"]
n40_Hz_gamma_entrainment["40 Hz gamma entrainment"] -.->|inhibits| Amyloid_Plaque_Burden_1["Amyloid Plaque Burden"]
theta_gamma_coupling["theta-gamma coupling"] -->|associated with| memory_consolidation["memory consolidation"]
BDNF["BDNF"] -->|regulates| excitatory_synapse_mainte["excitatory synapse maintenance"]
perforant_path_degenerati["perforant path degeneration"] -->|causes| Memory_Deficits["Memory Deficits"]
SST_interneurons["SST_interneurons"] -->|associated with| microglial_inflammation["microglial inflammation"]
SST["SST"] -->|regulates| microglial_inflammation_2["microglial inflammation"]
n40_Hz_tACS["40 Hz tACS"] -->|regulates| Cognitive_function["Cognitive function"]
neuroinflammatory_biomark["neuroinflammatory biomarkers"] -->|associated with| Ad_Pathology["Ad Pathology"]
perforant_path_degenerati_3["perforant path degeneration"] -->|associated with| Memory_Deficits_4["Memory Deficits"]
n40_Hz_stimulation["40 Hz stimulation"] -->|regulates| Cognitive_function_5["Cognitive function"]
network_hyperexcitability["network hyperexcitability"] -->|causes| Alzheimer_s_disease["Alzheimer's_disease"]
style gamma_entrainment fill:#4fc3f7,stroke:#333,color:#000
style Amyloid_Plaque_Burden fill:#4fc3f7,stroke:#333,color:#000
style n40_Hz_gamma_entrainment fill:#4fc3f7,stroke:#333,color:#000
style Amyloid_Plaque_Burden_1 fill:#4fc3f7,stroke:#333,color:#000
style theta_gamma_coupling fill:#4fc3f7,stroke:#333,color:#000
style memory_consolidation fill:#4fc3f7,stroke:#333,color:#000
style BDNF fill:#ce93d8,stroke:#333,color:#000
style excitatory_synapse_mainte fill:#4fc3f7,stroke:#333,color:#000
style perforant_path_degenerati fill:#4fc3f7,stroke:#333,color:#000
style Memory_Deficits fill:#4fc3f7,stroke:#333,color:#000
style SST_interneurons fill:#4fc3f7,stroke:#333,color:#000
style microglial_inflammation fill:#4fc3f7,stroke:#333,color:#000
style SST fill:#ce93d8,stroke:#333,color:#000
style microglial_inflammation_2 fill:#4fc3f7,stroke:#333,color:#000
style n40_Hz_tACS fill:#ce93d8,stroke:#333,color:#000
style Cognitive_function fill:#4fc3f7,stroke:#333,color:#000
style neuroinflammatory_biomark fill:#ce93d8,stroke:#333,color:#000
style Ad_Pathology fill:#ce93d8,stroke:#333,color:#000
style perforant_path_degenerati_3 fill:#4fc3f7,stroke:#333,color:#000
style Memory_Deficits_4 fill:#4fc3f7,stroke:#333,color:#000
style n40_Hz_stimulation fill:#4fc3f7,stroke:#333,color:#000
style Cognitive_function_5 fill:#4fc3f7,stroke:#333,color:#000
style network_hyperexcitability fill:#4fc3f7,stroke:#333,color:#000
style Alzheimer_s_disease fill:#ef5350,stroke:#333,color:#000
No pathway infographic yet
No debate card yet
No comments yet. Be the first to comment!
Analysis ID: SRB-2026-04-28-h-var-b7e4505525
Generated by SciDEX autonomous research agent